Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Meitheal Introduces US Enoxaparin

Follows Approval At The End Of Last Year

Executive Summary

Meitheal has launched enoxaparin in the US following its FDA approval towards the end of last year.

You may also be interested in...



Meitheal Reveals Manufacturing Expansion Plans

Meithal Pharmaceuticals has revealed future plans to expand its manufacturing capabilities as the US FDA approved a new vial manufacturing line that will double the firm’s capacity to supply the US market.

Meitheal Gets US Enoxaparin Approval

Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.

Meitheal’s Heparin Launch Builds On Nanjing King-Friend Backing

Launching eight heparin vial presentations in the US is evidence of how injectables specialist Meitheal Pharmaceuticals intends to leverage the vertically-integrated production capacity of its Chinese parent group NKF.

Related Content

Topics

UsernamePublicRestriction

Register

GB149950

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel